Cetuximab (Erbitux), an anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody used in the treatment of head and neck and colorectal cancer, so far faces no biosimilar challengers. However, Chinese researchers are reporting positive preclinical results for a proposed biosimilar, APZ001.
Cetuximab (Erbitux), an anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody used in the treatment of head and neck and colorectal cancer, so far faces no biosimilar challengers. However, Chinese researchers are reporting positive preclinical results for a proposed biosimilar, APZ001.
Previous studies have demonstrated that APZ001 has the same therapeutic effects as the reference product in a mouse model, and a pharmacokinetic (PK) assessment in Cynomolgus monkeys showed that the 2 products have similar PK, toxicology, and immunogenicity.
Click to read more about cetuximab.
In the current study's observation of mouse behavior, both the reference and biosimilar showed negative effects in terms of nervous excitability, autonomic and nonautonomic nervous function, nervous-muscle function, and coordination function. There was no significant difference in negative behavior between mice given the 2 drugs, however.
In an evaluation of the 2 drugs in Cynomolgus monkeys, no significant differences were recorded in heart function, though monkeys given APZ001 showed insignificant differences in heart rate and blood pressure from those given the reference, under anesthesia. No differences were observed between breath parameters or electrocardiogram results.
There were also no significant differences observed in drug-related urinary volume alteration between monkeys administered the 2 drugs. During periods of drug administration and recovery in rabbits, no abnormal reactions were observed in animals receiving either product.
In human tissues, both APZ001 and the reference showed positive signals in endocardium, alveolar epithelial cells, and surrounding vessels, and showed negative results in kidney and liver tissues.
The investigators concluded that, in their safety assessment and bioequivalence study of the 2 products, APZ001 and the reference showed highly similar effects in the animal models, and no severe adverse events were observed in any of the tested animals. APZ001, they conclude, may be a viable biosimilar for cetuximab.
Reference
Wang X, Guo J, Deng X, et al. Comparative safety assessments of the biosimilar APZ001 and Erbitux in pre-clinical animal models. Acta Cir Bras. 2018;33(8): 690-702. doi: 10.1590/s0102-865020180080000005.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.